As the Boomer generation approaches old age, chronic pain has become an epidemic.

According to an ABC News Poll, about 38 million adults in the U.S. experience chronic pain almost everyday and around 12 million citizens have tapped cannabis to ease the pain.

Up to this date, the available drugs for pain alleviation are limited to anti-depressants, opiates, and anti-steroidals. While they are effective they come with adverse side effects. As such many are turning to herbal treatment options such as cannabidiol (CBD).

Research & Advancements on CBD and Neuropathy

Back in 2015, the Canadian authority has approved the used of ‘Sativex’ for treating neuropathy. It is a prescription drug that is a mix of CBD and THC and is not much different than a full spectrum hemp extract that combines CBD and THC. Simply put, it is a cannabis extract with ethanol base, packaged up and branded by GW Pharmaceuticals.

Various clinical trials have proven the effectiveness of CBD + THC Sativex in managing neuropathy pain experienced by Multiple Sclerosis patients. The U.S. Food and Drug Authority has approved Sativex for trials to deal with neuropathic pain related with cancer.

While it is quite ironical, Western knowledge about the body’s pain system started from studying chile peppers, willow bark, opium poppies and cannabis plan. Pharmaceutical firms only start to formulate high addictive synthetic drugs like oxycontin, codeine and morphine out of the studies of these plants and their inherent medicinal values.

Before the early 2000s, pharmaceutical firms were unable to derive drugs from endocannabinoid because of the lack of commercial patentability and feasibility.  Due to their analgesic effect in pain control, cannabinoids are nonetheless well-known pain relievers. In fact, activating cannabinoid receptor (CB1 receptor) will result to quick alleviation of inflammation and pain. This is evident in reduced pain experienced by patients with fibromyalgia and intestinal pain with IBS upon receiving cannabis treatment.

A recent study involving rats showed encouraging evidence in controlling neuropathic pain, The researchers said that CBD was the non-psychoactive compound behind the antinociceptive behavior observed among rats as it is the only component existing in the extract at a high level that was to bind to CB1 receptor.

University of California’s Center for Medicinal Cannabis Research Director Dr. Igor Grant, compared the effectiveness of cannabis against selective serotonin reuptake inhibitors, gabapentin, tricyclic antidepressants, and anticonvulsants.  He found that except trycyclics, cannabis was more effective at neuropathic pain reduction.

The potential of cannabis in treating neuropathic pain is among the topics widely supported by medical research. Today, experts regard cannabinoids as holding the highest potency in relieving pain for many sufferers, mainly due to the fact that most prescription drugs for neuropathic pain are limited in effectiveness and come with harsh side effects.

Because of the inability of Western medicine to formulate an effective anti-neuropathic pain treatment, a lot of sufferers are resorting to cannabis, particularly CBD as an alternative option for managing pain.

The Promising Future of CBD and Neuropathy

To wrap up, CBD oil seems to have a very promising future in treating neuropathy and nerve pains among patients. It is being seen as an effective alternative minus the adverse effects common with prescription drugs. CBD is believed of having the capacity to reduce pain, thanks to its inherent antioxidant properties and ability to significantly and quickly lower inflammation. In fact, when compared with other popular antioxidants like Vitamin C (ascorbate) and Vitamin E (alpha-tocopherol), CBD beat them both in terms of efficacy with regards to reducing glutamate toxicity in neurons.